Canada · Delayed Price · Currency is CAD Lassonde Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q3 sales declined 2.3% excluding FX, while gross profit and adjusted shareholder profit grew. Temporary U.S. plant disruptions pressured costs and limited growth; FY2026 sales are expected slightly below prior year, with customer replacement and facility transition risks extending into 2027.
-
Gross profit rose 16% in Q2, driven by lower input costs, improved mix, and disciplined execution, despite sales declining slightly due to category softness and portfolio optimization. Adjusted EBITDA and profit grew strongly, while the company maintained a robust balance sheet and announced a share buyback.
-
Operating profit rose 22% despite lower sales, driven by pricing discipline and cost alignment. National brands gained share, while private label faced headwinds. Guidance for CAD 3 billion in 2026 is maintained, with no volume boost expected from the new facility this year.
Fiscal Year 2025
-
Record sales and profitability were achieved in 2025, with strong margin expansion and market share gains across all divisions. The outlook for 2026 targets CAD 3 billion in sales, supported by innovation, disciplined pricing, and capacity investments.
-
Q3 2025 saw 8.3% sales growth and a 23% rise in operating profit, driven by pricing and improved private label mix. Adjusted EPS hit a record, while net debt and leverage improved. Volatile commodity costs and trade uncertainty remain key risks.
-
Q2 sales rose 19% to CAD 742 million, while adjusted EBITDA increased 13% to CAD 84 million. FY2025 sales guidance is slightly above 10%, with commodity volatility, tariffs and working capital remaining key watchpoints.
-
The meeting featured a generational board transition, record financial results, and major U.S. expansion through acquisition and investment. All directors were elected, Deloitte was reappointed as auditor, and key risks such as commodity volatility and trade uncertainty were addressed.
-
Sales rose 22.8% to CAD 700 million, with strong market share gains and a 36% increase in adjusted EBITDA. Margin pressures from commodity costs were offset by price adjustments, and specialty food, including Summer Garden, delivered robust growth and profitability.
Fiscal Year 2024
-
Record 2024 results with sales over CAD 2.6B and strong EBITDA growth, driven by U.S. volume gains, Canadian pricing, and the Summer Garden acquisition. 2025 outlook targets 10% sales growth, with margin recovery expected after Q1 cost pressures and continued investment in U.S. expansion.
-
Q3 2024 saw strong sales and profit growth, driven by volume gains, efficiency improvements, and the Summer Garden acquisition. Major U.S. investments and ongoing innovation support a positive outlook, despite commodity cost pressures and global trade uncertainties.
-
Q2 saw 7.8% sales growth and 21% higher operating profit, driven by U.S. volume gains and Canadian pricing. The North Carolina expansion and Summer Garden acquisition support future growth, while 2024 sales guidance was raised to mid- to high-single digits.
-
The acquisition nearly doubles specialty food presence and expands U.S. reach, adding premium and health-oriented brands with strong growth potential. The $235M deal is accretive to margins and EPS, with synergies and integration investments expected to drive further value.